Apollo Health Ventures’ €157.5 Million Second-Generation Fund Structuring

YPOG advised Apollo Health Ventures on the deal.

The transatlantic Venture Capital Apollo Health Ventures announced the structuring its “Health Ventures Fund II”.

With capital commitments of $180 million (€157.5 million), the new fund reached its final closing while being oversubscribed. The new money was raised by Apollo’s existing international investor base as well as experienced and well-known new investors.

According to Apollo Health, the company will support the founding of new startups and finance existing businesses in the data-based biotechnology and healthcare technology sector. Based on groundbreaking scientific insights, Apollo focuses especially on investments that have the potential to treat, prevent or even completely cure age-related diseases to extend the human lifespan. 

Apollo Health Ventures is a transatlantic Venture Capital specializing in the development and financing of data-driven biotechnology and healthcare technology companies. Apollo Health Ventures invests while Seed or Early-Stage financing rounds and develops companies in the Aging Health sector. Apollo’s team includes entrepreneurs, experienced biotech investors, and scientists with significant expertise in life science investing and company formation.

The YPOG team included Jens Kretzschmann (Picture – Co-Lead/Structuring, Tax), Partner; Dr. Julian Albrecht (Co-Lead/Structuring, Tax), Associated Partner; Dr. Niklas Ulrich (Regulatory), Associate.

Involved fees earner: Julian Albrecht – YPOG; Jens Kretzschmann – YPOG; Niklas Ulrich – YPOG;

Law Firms: YPOG;

Clients: Apollo Health Ventures;

Federica Tiefenthaler

Author: Federica Tiefenthaler